Léčba erlotinibem nemocných s nemalobuněčnými karcinomy plic - efekt snížené dávky při závažných nežádoucích účincích

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Erlotinib therapy of patients with NSCLC - dose reduction in patients with severe adverse reactions
Authors

PEŠEK Miloš KREJČÍ Jana SKŘIČKOVÁ Jana ZATLOUKAL Petr KOLEK Vítězslav SALAJKA František KOUBKOVÁ Leona SIXTOVÁ Dimka PETRUŽELKA Luboš ROUBEC Jaromír VYZULA Rostislav PAVLÍK Tomáš MINÁRIK M.

Year of publication 2010
Type Article in Proceedings
Conference XXXIV. Brněnské onkologické dny
MU Faculty or unit

Faculty of Medicine

Citation
Field Pneumology
Keywords erlotinib; NSCLC; dose reduction; adverse reaction
Description This contribution to the conference was dedicated to the analysis of dose reduction effect in patients treated for NSCLC with erlotinib who suffered from severe adverse reactions.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info